SCYNEXIS, Inc. (SCYX) financial statements (2021 and earlier)
Company profile
| Business Address |
1 EVERTRUST PLAZA JERSEY CITY, NJ 07302-6548 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 48 | 44 | 44 | 59 | 47 | 32 | ||
| Cash and cash equivalents | 42 | 11 | 11 | 36 | 47 | 32 | ||
| Short-term investments | 6 | 33 | 32 | 23 | ||||
| Restricted cash and investments | 0 | |||||||
| Receivables | 0 | 0 | 0 | 1 | ||||
| Prepaid expense | 0 | 0 | 0 | 0 | 0 | 1 | ||
| Deferred costs | 0 | 0 | ||||||
| Other current assets | 1 | 0 | 0 | 0 | 0 | 0 | ||
| Other undisclosed current assets | 3 | 7 | 0 | 0 | 0 | 1 | ||
| Total current assets: | 52 | 51 | 45 | 59 | 48 | 35 | ||
| Noncurrent Assets | ||||||||
| Operating lease, right-of-use asset | 3 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 0 | 1 | 0 | 5 | ||||
| Restricted cash and investments | 0 | 0 | ||||||
| Deferred costs | 0 | 0 | ||||||
| Other noncurrent assets | 1 | 1 | 1 | 0 | 0 | 0 | ||
| Other undisclosed noncurrent assets | 0 | 0 | 0 | |||||
| Total noncurrent assets: | 5 | 2 | 1 | 0 | 1 | 5 | ||
| TOTAL ASSETS: | 57 | 53 | 46 | 60 | 49 | 40 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 11 | 6 | 6 | 3 | 4 | 4 | ||
| Accounts payable | 7 | 4 | 4 | 2 | 1 | 1 | ||
| Accrued liabilities | 4 | 2 | 2 | 1 | 3 | 2 | ||
| Employee-related liabilities | 0 | |||||||
| Debt | 0 | 4 | ||||||
| Deferred revenue and credits | ✕ | ✕ | 0 | 0 | 0 | 0 | ||
| Other undisclosed current liabilities | 0 | 3 | (0) | |||||
| Total current liabilities: | 11 | 6 | 10 | 4 | 7 | 4 | ||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 3 | 15 | 10 | 14 | ||||
| Long-term debt, excluding current maturities | 15 | 10 | 14 | |||||
| Operating lease, liability | 3 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt | 0 | 0 | 1 | 2 | ||||
| Deferred revenue and credits | ✕ | ✕ | 0 | 0 | 1 | 2 | ||
| Other undisclosed noncurrent liabilities | 30 | 1 | 4 | 7 | ||||
| Total noncurrent liabilities: | 33 | 16 | 14 | 21 | 1 | 2 | ||
| Total liabilities: | 44 | 22 | 24 | 25 | 7 | 6 | ||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent, including: | 13 | 31 | 21 | 35 | 42 | 33 | ||
| Additional paid in capital | 284 | 249 | 227 | 215 | 192 | 151 | ||
| Accumulated deficit | (271) | (218) | (205) | (180) | (150) | (118) | ||
| Other undisclosed stockholders' equity attributable to parent | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Total stockholders' equity: | 13 | 31 | 21 | 35 | 42 | 33 | ||
| TOTAL LIABILITIES AND EQUITY: | 57 | 53 | 46 | 60 | 49 | 40 | ||
Income statement (P&L) ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 0 | 0 | 0 | 0 | 0 | 19 | |
| Revenue, net | ✕ | ✕ | 0 | 0 | 2 | 12 | |
| Cost of revenue | (15) | ||||||
| Gross profit: | 0 | 0 | 0 | 0 | 0 | 4 | |
| Operating expenses | (49) | (30) | (27) | (28) | (29) | (16) | |
| Operating loss: | (49) | (30) | (26) | (28) | (28) | (12) | |
| Nonoperating income (expense) | (5) | 11 | 1 | (2) | 0 | 8 | |
| Investment income, nonoperating | 2 | 0 | (0) | (0) | |||
| Interest and debt expense | (1) | (2) | (1) | (0) | (1) | ||
| Loss from continuing operations before equity method investments, income taxes: | (55) | (21) | (27) | (30) | (28) | (6) | |
| Other undisclosed income from continuing operations before income taxes | 1 | 2 | 1 | 0 | |||
| Loss from continuing operations before income taxes: | (54) | (19) | (25) | (30) | (28) | (6) | |
| Income tax benefit | 7 | ||||||
| Loss from continuing operations: | (54) | (12) | (25) | (30) | (28) | (6) | |
| Loss from discontinued operations | (4) | ||||||
| Loss before gain (loss) on sale of properties: | (54) | (12) | (25) | (30) | (33) | (6) | |
| Other undisclosed net income | 1 | ||||||
| Net loss: | (54) | (12) | (25) | (30) | (33) | (4) | |
| Other undisclosed net income attributable to parent | 0 | ||||||
| Net loss attributable to parent: | (54) | (12) | (25) | (30) | (33) | (4) | |
| Preferred stock dividends and other adjustments | (1) | ||||||
| Other undisclosed net loss available to common stockholders, basic | (1) | ||||||
| Net loss available to common stockholders, basic: | (54) | (12) | (25) | (30) | (33) | (6) | |
| Dilutive securities, effect on basic earnings per share | (10) | ||||||
| Net loss available to common stockholders, diluted: | (54) | (12) | (25) | (30) | (33) | (16) | |
Comprehensive Income ($ in millions)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (54) | (12) | (25) | (30) | (33) | (4) | |
| Comprehensive loss, net of tax, attributable to parent: | (54) | (12) | (25) | (30) | (33) | (4) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.